PMID- 36454284
OWN - NLM
STAT- MEDLINE
DCOM- 20221223
LR  - 20230325
IS  - 1473-5636 (Electronic)
IS  - 0960-8931 (Linking)
VI  - 33
IP  - 1
DP  - 2023 Feb 1
TI  - Talimogene laherparepvec monotherapy for head and neck melanoma patients.
PG  - 66-70
LID - 10.1097/CMR.0000000000000866 [doi]
AB  - Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus, type 1, 
      intralesionally administered in patients with stage IIIB/C-IVM1a unresectable 
      melanoma. When surgery is not a treatment option in the head and neck region, 
      T-VEC can be an elegant alternative to systemic immunotherapy. Ten patients with 
      metastatic melanoma in the head and neck region started treatment with T-VEC 
      monotherapy at the Netherlands Cancer Institute. We collected data on response, 
      adverse events (AEs), and baseline characteristics. For response evaluation, we 
      used clinical evaluation with photography, 3-monthly PET/computed tomography 
      (PET/CT) using 18F-fluoro-2-D-deoxyglucose, and histological biopsies. Median age 
      at baseline was 78.2 (35-97) years with a median follow-up of 11.6months. Of 
      these 10 patients, 5 had a complete response (CR), 3 had a partial response, 1 
      had stable disease and 1 showed progressive disease (PD) as their best response. 
      Best overall response rate (ORR) was 80%. Median progression-free survival was 
      10.8 months (95% confidence interval, 2.2-19.4). Grade 1 AEs occurred in all 
      patients. Mostly, these consisted of fatigue, influenza-like symptoms, and 
      injection site pain. PET-CT and histological biopsies proved to be clinically 
      useful tools to evaluate treatment response for T-VEC monotherapy, confirming pCR 
      or PD to stage IV disease requiring systemic treatment. ORR for T-VEC monotherapy 
      for melanoma in the head and neck region at our institute was 80% with 50% 
      achieving a CR. This realworld data demonstrates promising results and suggests 
      T-VEC can be an alternative to systemic therapy in this select, mostly elderly 
      patient population.
CI  - Copyright (c) 2022 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Franke, Viola
AU  - Franke V
AD  - Departments of Surgical Oncology.
FAU - Stahlie, Emma H A
AU  - Stahlie EHA
AD  - Departments of Surgical Oncology.
FAU - Klop, Willem M C
AU  - Klop WMC
AD  - Head and Neck Surgery.
FAU - Zuur, Charlotte L
AU  - Zuur CL
AD  - Head and Neck Surgery.
FAU - Berger, Danique M S
AU  - Berger DMS
AD  - Head and Neck Surgery.
FAU - van der Hiel, Bernies
AU  - van der Hiel B
AD  - Nuclear Medicine.
FAU - van de Wiel, Bart A
AU  - van de Wiel BA
AD  - Pathology at the Netherlands Cancer Institute - Antoni van Leeuwenhoek, 
      Amsterdam, The Netherlands.
FAU - Wouters, Michel W J M
AU  - Wouters MWJM
AD  - Departments of Surgical Oncology.
FAU - van Houdt, Winan J
AU  - van Houdt WJ
AD  - Departments of Surgical Oncology.
FAU - van Akkooi, Alexander C J
AU  - van Akkooi ACJ
AD  - Department of Surgical Oncology/ Faculty Member Melanoma Institute Australia, The 
      Poche Centre, Cammeraygal Land, Wollstonecraft, Australia.
LA  - eng
PT  - Journal Article
DEP - 20221129
PL  - England
TA  - Melanoma Res
JT  - Melanoma research
JID - 9109623
RN  - 0 (talimogene laherparepvec)
SB  - IM
MH  - Humans
MH  - Aged
MH  - Aged, 80 and over
MH  - *Melanoma/pathology
MH  - Positron Emission Tomography Computed Tomography
MH  - *Skin Neoplasms/pathology
MH  - *Oncolytic Virotherapy/adverse effects
MH  - Immunotherapy/methods
EDAT- 2022/12/02 06:00
MHDA- 2022/12/24 06:00
CRDT- 2022/12/01 11:14
PHST- 2022/12/02 06:00 [pubmed]
PHST- 2022/12/24 06:00 [medline]
PHST- 2022/12/01 11:14 [entrez]
AID - 00008390-202302000-00007 [pii]
AID - 10.1097/CMR.0000000000000866 [doi]
PST - ppublish
SO  - Melanoma Res. 2023 Feb 1;33(1):66-70. doi: 10.1097/CMR.0000000000000866. Epub 
      2022 Nov 29.